Material Event (Form 8-K)

Exhibits are filed herewith in connection with the registered direct offering (the "Registered Direct Offering") by Outlook Therapeutics, Inc. (the "Company") of 8,539,709 shares of the Company's common stock, $0.01 par value per share, to GMS Ventures and Investments (the "Purchaser") pursuant to that certain securities purchase agreement entered into on May 28, 2026, by and between the Company and the Purchaser. The Registered Direct Offering was made pursuant to the Company's effective registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission on March 28, 2024 and which became effective on April 5, 2024 and a related base prospectus and prospectus supplement thereunder.